FDA Rejects Replimune’s Skin Cancer Drug for the Second Time
FDA again rejects Replimune’s skin cancer drug RP1, saying studies don’t prove it works; shares halted, setback for company.
/ 11 items
#BMY↓
Janux Therapeutics Partners with Bristol Myers Squibb in Major Cancer Drug Deal
Janux Therapeutics announces collaboration with Bristol Myers Squibb to develop novel tumor-activated cancer therapy, with potential payments up to $850 million.
Trump Administration Secures Drug Price Cuts from Nine Major Pharmaceutical Companies
Nine pharmaceutical giants including Merck and GSK agree to slash U.S. drug prices to match other wealthy nations under new Trump administration deals, offering discounts up to 70%.
BofA Upgrades Bristol Myers to Buy on Strong Pipeline Outlook
Bank of America upgrades Bristol Myers Squibb to Buy, raising its price target to $61, citing a strong R&D pipeline and multiple upcoming catalysts through 2026.
Guggenheim Upgrades Bristol Myers to Buy with $62 Target
Guggenheim raises Bristol Myers to Buy, citing low expectations, strong pipeline, and potential entry point for value-focused investors.
MapLight Therapeutics Gains from Bristol Myers’ ADEPT-2 Study Update
MapLight Therapeutics sees upside as Bristol Myers continues ADEPT-2 Alzheimer’s psychosis trial despite site irregularities, with potential catalysts for 2026.